Correlation of progression-free survival at 6 months (PFS6) with overall survival at 12 months (OS12) in an analysis of 10 trials of second-line therapy for advanced urothelial carcinoma (UC).
Maughan B, Boucher K, Agarwal N, Choueiri T, Qu A, Vogelzang N, Fougeray R, Niegisch G, Albers P, Wong Y, Ko Y, Sridhar S, Galsky M, Petrylak D, Vaishampayan U, Beer T, Sternberg C, Rosenberg J, Molins J, Sonpavde G. Correlation of progression-free survival at 6 months (PFS6) with overall survival at 12 months (OS12) in an analysis of 10 trials of second-line therapy for advanced urothelial carcinoma (UC). Journal Of Clinical Oncology 2012, 30: 4525-4525. DOI: 10.1200/jco.2012.30.15_suppl.4525.Peer-Reviewed Original ResearchSecond-line therapyAdvanced urothelial carcinomaPhase II trialUrothelial carcinomaIndividual-level agreementResponse rateII trialIndividual patient progressionProgression-free survivalAssociation of responsePearson's chi-square testDuration of benefitSignificant unmet needRandom-effects modelChi-square testPearson correlationPrimary endpointVisceral metastasesOverall survivalPerformance statusMedian ageYates' continuity correctionPatient progressionIntermediate endpointsPFS6